{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:17:54Z","timestamp":1787951874142,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.oret.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:13:44Z","timestamp":1784733224000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Faricimab for High-Need Aflibercept 2 mg\u2013Treated Neovascular Age-Related Macular Degeneration: A Randomized Comparator-Controlled Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-8084","authenticated-orcid":false,"given":"Monja","family":"Michelitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Strini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-6459","authenticated-orcid":false,"given":"Laura","family":"Posch-Pertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Wallisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Djavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2533-7067","authenticated-orcid":false,"given":"Andreas","family":"Wedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2026.07.009_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2026.07.009_bib3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2026.07.009_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.009_bib5","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.009_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","article-title":"Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis","volume":"37","author":"Rosenberg","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.07.009_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.oret.2025.01.010","article-title":"Persistence of retinal fluid after anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Yap","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.009_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.009_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.009_bib10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00417-021-05478-5","article-title":"A 10-point score classification for anti-VEGF response in exudative AMD","volume":"260","author":"Mon\u00e9s","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.009_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3 trials, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.07.009_bib12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.009_bib13","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.2147\/OPTH.S395279","article-title":"Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.009_bib14","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/OPTH.S424315","article-title":"One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.009_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.009_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.009_bib17","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.07.009_bib18","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s00417-025-06903-9","article-title":"Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase","volume":"263","author":"Eckardt","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.009_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab","volume":"9","author":"Sim","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.009_bib20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/IAE.0000000000004322","article-title":"Real-world long-term outcomes of intravitreal faricimab in previously treated chronic neovascular age-related macular degeneration","volume":"45","author":"Ambati","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.07.009_bib21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","article-title":"One-year outcomes after switching to faricimab in eyes with pretreated neovascular age-related macular degeneration: a Swiss Retina Research Network Report","volume":"9","author":"Grimaldi","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.009_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/ceo.14589","article-title":"Outcomes after switching to faricimab in neovascular age-related macular degeneration: data from the Fight Retinal Blindness! registry","volume":"53","author":"Hunt","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810204","article-title":"Efficacy of simultaneous VEGF-A\/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization","volume":"11","author":"Foxton","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.oret.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026003684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026003684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:30:04Z","timestamp":1787949004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026003684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"alternative-id":["S2468653026003684"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.07.009","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faricimab for High-Need Aflibercept 2 mg\u2013Treated Neovascular Age-Related Macular Degeneration: A Randomized Comparator-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}